[Chronic lymphocytic leukemia: current standards and novel approaches]

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in Western countries, primarily affecting elderly individuals.
• Current standard treatments for CLL are stratified by patient age and fitness, with distinct regimens for younger and older populations.
• Specific genetic factors, such as 17p deletion or TP53 mutation, indicate ultra-high risk and influence treatment selection.

Purpose of the Study:

• To review established and emerging treatment options for chronic lymphocytic leukemia (CLL).
• To highlight the impact of newly approved targeted therapies on CLL management.
• To discuss future directions in CLL treatment, focusing on novel combinations and the goal of achieving a cure.

Main Methods:

• Review of current phase III trial data for standard CLL therapies.
• Analysis of clinical trial results for newly approved targeted agents.
• Discussion of ongoing and planned clinical trials investigating novel drug combinations and sequences.

Main Results:

• Established regimens include fludarabine, cyclophosphamide, and rituximab (FCR) for younger patients, and bendamustine with rituximab (BR) or ofatumumab for elderly fit patients.
• Newer oral kinase inhibitors (idelalisib, ibrutinib) and a direct apoptosis inducer (ABT-199) show high efficacy and tolerability in ultra-high risk and relapsed/refractory CLL.
• These novel agents are poised to significantly alter the treatment landscape for CLL.

Conclusions:

• Treatment decisions in CLL are increasingly personalized based on patient factors and genetic risk.
• Targeted therapies represent a significant advancement, offering improved outcomes and tolerability.
• Future research will focus on optimizing combinations and sequences of novel agents to maximize remission duration and potentially cure CLL.